VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity

VYNE Therapeutics Inc.

VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.
PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.
Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.
No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.